All In Biotech

Drug Trial Radar · NCT05085561

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

62

Actual

Start

Mar 17, 2022

Primary completion

Jun 30, 2025

Study completion Jun 30, 2025

Sponsor

Lead sponsor
Recursion Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Oct 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic cerebral cavernous malformation (CCM).

Conditions

  • Cerebral Cavernous Malformation

Interventions

  • REC-994Drug

    REC-994 200 mg tablets

  • PlaceboDrug

    Placebo Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to a maximum of 1201 days

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Xenoscience Inc

    Phoenix, Arizona

  • UCLA

    Los Angeles, California

  • Stanford University

    Palo Alto, California

  • University of Florida

    Gainesville, Florida

  • Lyerly Neurosurgery

    Jacksonville, Florida

  • Cleveland Clinic Florida

    Port Saint Lucie, Florida

  • Emory

    Atlanta, Georgia

  • Valley Hospital

    Ridgewood, New Jersey

  • Columbia University Medical Center

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • The University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Virginia

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.